drugset / Trial / NCT00911573

Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

NCT00911573

RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of this study is to compare the safety and efficacy of tigecycline versus clindamycin (including subjects treated with vancomycin) in pediatric subjects (aged 8 to 17 years) with complicated skin and skin structure infections (cSSSI), including those caused by methicillin-resistant staphylococcus aureus (MRSA).

Timeline

Start
2011-08
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clindamycin Unknown 10 mg/kg Intravenous
Subject Tigecycline Small molecule 50 mg Intravenous
Comparator Vancomycin Other / unclassified 15 mg/kg Intravenous